The risks of thrombolysis in patients without acute myocardial infarction

This publication has 10 references indexed in Scilit:

• Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. The GREAT Group.
  BMJ, 1993
• Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group.
  BMJ, 1992
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
  Published by Elsevier ,1992
• Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors
  Journal of the American College of Cardiology, 1992
• Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods
  American Heart Journal, 1990
• Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
  The American Journal of Medicine, 1988
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988
• Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
  Journal of the American College of Cardiology, 1987
• A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)
  New England Journal of Medicine, 1986
• Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction
  Journal of the American College of Cardiology, 1986